ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions
View by Date

Sunday, November 13, 2016

9:00AM-11:00AM
Abstract Number: 888
Prevalence of Takayasu Arteritis in Young Women Presenting with Acute Ischemic Heart Disease
Vasculitis - Poster I: Large Vessel Vasculitis and Polymyalgia Rheumatica
9:00AM-11:00AM
Abstract Number: 738
Preventive Effect of Combined Treatment with Bisphosphonate and Vitamin D on Atherosclerosis in Patients with Systemic Lupus Erythematosus
Systemic Lupus Erythematosus – Clinical Aspects and Treatment - Poster I: Clinical Trial Design and Current Therapies
9:00AM-11:00AM
Abstract Number: 771
Preventive Effects of Glucocorticoids on Progression of Atherosclerosis in Japanese Patients with SLE
Systemic Lupus Erythematosus – Clinical Aspects and Treatment - Poster I: Clinical Trial Design and Current Therapies
9:00AM-11:00AM
Abstract Number: 846
Progression of Left Ventricular Myocardial Dysfunction in Systemic Sclerosis: Using Speckle Tracking Strain Echocardiography to Identify Patients at Risk
Systemic Sclerosis, Fibrosing Syndromes, and Raynaud's – Clinical Aspects and Therapeutics - Poster I
9:00AM-11:00AM
Abstract Number: 539
Promis Short Forms Are Relevant to People Living with RA: Results of Cognitive Debriefing Interviews
Rheumatoid Arthritis – Clinical Aspects - Poster I: Clinical Characteristics/Presentation/Prognosis
9:00AM-11:00AM
Abstract Number: 213
Prophylaxis for Infusion Reactions to Pegloticase: An Analyis of Two Different Corticosteroid Pre-Infusion Regimens in US Community Rheumatology Practices
Metabolic and Crystal Arthropathies - Poster I: Clinical Practice
9:00AM-11:00AM
Abstract Number: 415
Proposal for a Damage Index for Juvenile Idiopathic Arthritis Related Uveitis from the Multinational Interdisciplinary Working Group for Uveitis in Childhood  Group (MIWGUC)
Pediatric Rheumatology – Clinical and Therapeutic Aspects - Poster I: Juvenile Idiopathic Arthritis, Uveitis
9:00AM-11:00AM
Abstract Number: 414
Proposal for the Definition of Inactivity of Juvenile Idiopathic Arthritis Related Uveitis from the Multinational Interdisciplinary Working Group for Uveitis in Childhood  Group (MIWGUC)
Pediatric Rheumatology – Clinical and Therapeutic Aspects - Poster I: Juvenile Idiopathic Arthritis, Uveitis
9:00AM-11:00AM
Abstract Number: 645
Prospective Observational Real-Life Study (STRATEGE) Shows the Efficacy of Treat-to-Target Strategy and Methotrexate Monotherapy Optimization in Patients with Established Rheumatoid Arthritis
Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy - Poster I
9:00AM-11:00AM
Abstract Number: 636
Prospective, Intervention, Multicenter Study of Utility of Biologic Drug Monitoring with Respect to the Efficacy and Cost of Adalimumab Tapering in Patients with Rheumatic Diseases (34-week descriptive data)
Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy - Poster I
9:00AM-11:00AM
Abstract Number: 183
Protective Role of Mucosal-Associated Invariant T (MAIT) Cells in an Imiquimod-Induced Psoriasis Model
Innate Immunity and Rheumatic Disease - Poster I
9:00AM-11:00AM
Abstract Number: 174
Protein Modified with Citrulline and/or Malondialdehyde-Acetaldehyde Bind to Different Scavenger Receptors
Innate Immunity and Rheumatic Disease - Poster I
9:00AM-11:00AM
Abstract Number: 822
Pulmonary Fibrosis in Mixed Connective Tissue Disease – Results from an Unselected Longitudinal Cohort
Systemic Sclerosis, Fibrosing Syndromes, and Raynaud's – Clinical Aspects and Therapeutics - Poster I
9:00AM-11:00AM
Abstract Number: 142
Quality Assessment of Ultrasound Guided Synovial Biopsies Performed in Clinical Practice
Imaging of Rheumatic Diseases - Poster I: Ultrasound and Emerging Technologies
9:00AM-11:00AM
Abstract Number: 642
Quality of Life Outcomes Following Therapy with Chs-0214 and Etanercept (Enbrel): Randomized, Double-Blind Study in Subjects with Rheumatoid Arthritis
Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy - Poster I
  • «Previous Page
  • 1
  • …
  • 42
  • 43
  • 44
  • 45
  • 46
  • …
  • 70
  • Next Page»
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology